While MRE based on 2D gradient recalled echo (GRE) MRI is FDA approved at 1.5T, the utility of 2D GRE MRE in the liver at 3T is limited by susceptibility effects and relatively long echo times that results in less SNR. MRE performance, particularly at 3T, can be improved by developing a faster technique that is less sensitive to liver T2* effects. In this work, we describe the development of SE-EPI MRE and its validation with respect to 2D GRE MRE in phantoms and healthy volunteers.
This abstract and the presentation materials are available to members only; a login is required.